Drugs / MB-106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05360238 | May 2022 → Apr 2024 | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma | Mustang Bio | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 29
| Date | Issuer | Release |
|---|---|---|
| 2025-08-27 | Moleculin Biotech, Inc. | Results Moleculin Issues New Positive AML Overall Survival Data: moleculin.com ↗
Median OS for the intent to treat (ITT) Population (1L-7L): 9 months (n=22; 13 subjects experienced an event, 9 subjects censored) |
| 2024-11-18 | Moleculin Biotech, Inc. | Results New Findings Show Moleculin’s Annamycin Overcomes Resistance to Venetoclax in AML moleculin.com ↗
New data from MB-106 trial show median overall survival of 11.6 months in subjects receiving AnnAraC as 2nd line therapy |
| 2024-06-17 | Mustang Bio, Inc. | Results Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy mustangbio.com ↗
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months |
| 2024-06-14 | Moleculin Biotech, Inc. | Results Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial moleculin.com ↗
Current median durability of response (mDOR) of CRc’s = 6 months and increasing (n=9) |
| 2024-05-07 | Moleculin Biotech, Inc. | Results Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data moleculin.com ↗
Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line, with median durability at 4.9 months and climbing |
| 2024-03-25 | Moleculin Biotech, Inc. | Results Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial moleculin.com ↗
Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects |
| 2024-01-24 | Moleculin Biotech, Inc. | Results Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 moleculin.com ↗
MB-106 preliminary results: Intent to Treat CR rate of 40% plus a CR/ CRi rate of 47% (N=15); Dosed Per Protocol CR rate of 46% plus a CR/CRi rate of 54% (N=13) |
| 2023-12-11 | Moleculin Biotech, Inc. | Results Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting moleculin.com ↗
CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability |
| 2023-12-11 | Mustang Bio, Inc. | Results Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting mustangbio.com ↗ |
| 2023-11-13 | Moleculin Biotech, Inc. | Results Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months moleculin.com ↗
MB-106: CR rate of 38% (N=8) with durability up to 8 months |
| 2023-11-02 | Mustang Bio, Inc. | Results Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting mustangbio.com ↗
Updated interim data from Mustang’s multicenter Phase 1/2 clinical trial demonstrate favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients |
| 2023-08-16 | Mustang Bio, Inc. | Results Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy mustangbio.com ↗
Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy |
| 2023-08-10 | Moleculin Biotech, Inc. | Results Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones moleculin.com ↗
Announces a preliminary CR/CRi rate of 33% (n=6) in the Phase 1B portion of its MB-106 clinical trial |
| 2023-06-15 | Mustang Bio, Inc. | Results Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy mustangbio.com ↗
10 out of 20 patients remain in complete remission for more than a year |
| 2023-06-12 | Mustang Bio, Inc. | Results Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy mustangbio.com ↗
Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months |
| 2023-05-02 | Moleculin Biotech, Inc. | Results Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) moleculin.com ↗
Preliminary results demonstrate a durable complete response at starting dose level in elderly subject |
| 2022-10-27 | Mustang Bio, Inc. | Results Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia mustangbio.com ↗
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia |
| 2022-06-22 | Mustang Bio, Inc. | Regulatory Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia mustangbio.com ↗ |
| 2022-06-13 | Mustang Bio, Inc. | Results Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy mustangbio.com ↗
94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy |
| 2022-05-12 | Mustang Bio, Inc. | Results Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress mustangbio.com ↗
Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma |
| 2022-04-25 | Mustang Bio, Inc. | Results Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia mustangbio.com ↗
The data, which were presented by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutch and University of Washington, at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (“ASTCT”) and Center for International Blood & Marrow Transplant Research (“CIBMTR”), demonstrated high efficacy and a very favorable safety profile in all patients (n=25). |
| 2021-12-13 | Mustang Bio, Inc. | Results Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia mustangbio.com ↗
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”). |
| 2021-11-04 | Mustang Bio, Inc. | Results Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting mustangbio.com ↗
The overall response rate (“ORR”) was 94% (15/16) with a complete response (“CR”) rate of 62% (10/16). |
| 2021-06-11 | Mustang Bio, Inc. | Results Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia mustangbio.com ↗ |
| 2021-05-12 | Mustang Bio, Inc. | Results Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress mustangbio.com ↗
Cytokine release syndrome occurred in 3 patients (25%): 2 patients with grade 1 and 1 patient with grade 2. |
| 2021-05-10 | Mustang Bio, Inc. | Regulatory Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy mustangbio.com ↗ |
| 2020-12-07 | Mustang Bio, Inc. | Results Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma mustangbio.com ↗
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”). |
| 2020-11-04 | Mustang Bio, Inc. | Results Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting mustangbio.com ↗
No dose-limiting toxicity was observed. |
| 2020-02-18 | Mustang Bio, Inc. | Results Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106 mustangbio.com ↗
The subject achieved a complete response |
All press releases naming this drug 39 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05360238 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor t-cells (CAR-T cells)” NCT05360238 ↗ |
| Route | Intravenous | “single intravenous infusion up to 3.3 x 10e7 chimeric antigen receptor t-cells (CAR-T cells)/kg” NCT05360238 ↗ |